# Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Source: https://onco.cc/trials/nct05987956/  
OnCo record `nct05987956` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Alectinib in non-small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.

## Summary

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT05987956 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2026-03-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: ALECENSA - alectinib hydrochloride capsule.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05987956
- Phase: 2/3
- Setting: Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
- Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT05987956: https://clinicaltrials.gov/study/NCT05987956

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05987956.json